

ELECTRONIC SUPPORTING INFORMATION:

Achieving molecular stability of racemic 4-O-benzyl-*myo*-inositol-1,3,5-orthoformate through crystal formation

Richa Sardessai^a, Shobhana Krishnaswamy^b, Mysore S. Shashidhar^{a*}

^a Division of Organic Chemistry, National Chemical Laboratory – Council of Scientific and Industrial Research (CSIR), Pashan Road, Pune - 411008

^b Centre for Materials Characterization, National Chemical Laboratory – Council of Scientific and Industrial Research (CSIR), Pashan Road, Pune - 411 008


Table of contents:

FIGURE	CONTENT	PAGE
Figure S1	IR spectra of racemic 4- <i>O</i> -benzyl- <i>myo</i> -inositol-1,3,5-orthoformate (4)	
	a) Form I crystals	S3
	b) Gummy state 4B	S3
	c) Amorphous solid 4C	S4
	d) solid 4D	S4
	e) Amorphous sample 4C heated for 12 h at 130 °C	S5
Figure S2	IR spectra of racemic 4- <i>O</i> -benzyl- <i>myo</i> -inositol-1,3,5-orthoacetate (5)	
	a) Freshly prepared	S6
	b) Stored at ambient temperature	S6
	c) Amorphous solid	S7
	d) Heated sample	S7
Figure S3	IR spectra of racemic 4- <i>O</i> -benzyl- <i>myo</i> -inositol-1,3,5-orthobenzoate (6)	
	a) Freshly prepared	S8
	b) Stored at ambient temperature	S8
	c) Heated sample	S9
Figure S4	¹ H NMR spectra (CDCl ₃) of racemic 4- <i>O</i> -benzyl- <i>myo</i> -inositol-1,3,5-orthoformate (4)	
	a) Sample 4A	S10
	b) Sample 4B	S11


	c) Sample 4D	S12
	d) Form I crystals	S13
Figure S5	^1H NMR spectrum (CDCl_3) of racemic 4- <i>O</i> -benzyl- <i>myo</i> -inositol-1,3,5-orthoacetate (5)	S14
Figure S6	^1H NMR spectrum (CDCl_3) of heated sample of racemic 4- <i>O</i> -benzyl- <i>myo</i> -inositol-1,3,5-orthoacetate (5).	S15
Figure S7	^1H NMR spectrum (CDCl_3) of racemic 4- <i>O</i> -benzyl- <i>myo</i> -inositol-1,3,5-orthobenzoate (6)	S16
Figure S8	^1H NMR spectrum (CDCl_3) of heated sample of racemic 4- <i>O</i> -benzyl- <i>myo</i> -inositol-1,3,5-orthobenzoate (6)	S17
Figure S9	Simulated PXRD patterns for crystals of 4	S18
Figure S10	Overlap of PXRD patterns of sample 4D and Form I crystals	S19
Figure S11	Overlap of PXRD patterns of sample 4D and Form II crystals	S20
Figure S12	PXRD patterns of sample 4D , Form I and Form II crystals	S21

Figure S1. IR spectra of racemic 4-*O*-benzyl-*myo*-inositol-1,3,5-orthoformate (**4**)


a) Form I crystals (nujol)




b) Gummy **4B** (neat)



c) Amorphous solid sample of **4C** (nujol)



d) Solid 4D



e) Amorphous solid **4C** heated for 12 h at 130 °C (neat)






Figure S2. IR spectra of racemic 4-*O*-benzyl-*myo*-inositol-1,3,5-orthoacetate (**5**)


a) Freshly prepared **5** (CDCl_3)



b) **5** stored at ambient temperature for a month (neat)



c) Amorphous solid **5** (nujol):



d) **5** Heated at 120 °C for 6 hours (Nujol):






Figure S3. IR spectra of racemic 4-*O*-benzyl-*myo*-inositol-1,3,5-orthobenzoate (**6**)

a) Freshly prepared **6** (CDCl_3)



b) **6** stored at ambient temperature for a month (neat)



c) **6** Heated at 120°C for 6 hours (nujol)







Figure S4. a) ^1H NMR spectrum (CDCl_3) of racemic 4-*O*-benzyl-*myo*-inositol-1,3,5-orthoformate (sample **4A**).



b) ^1H NMR spectrum (CDCl_3) of racemic 4-*O*-benzyl-*myo*-inositol-1,3,5-orthoformate (sample 4B).



c) ^1H NMR spectrum (CDCl_3) of racemic 4-*O*-benzyl-*myo*-inositol-1,3,5-orthoformate (**4D**).



d) ^1H NMR spectrum (CDCl_3) of racemic 4-*O*-benzyl-*myo*-inositol-1,3,5-orthoformate (Form I crystals).




Figure S5. ^1H NMR spectrum (CDCl_3) of racemic 4-*O*-benzyl-*myo*-inositol-1,3,5-orthoacetate (5)




Figure S6. ^1H NMR spectrum (CDCl_3) of heated sample of racemic 4-*O*-benzyl-*myo*-inositol - 1,3,5-orthoacetate (**5**).




Figure S7. ^1H NMR spectrum (CDCl_3) of racemic 4-*O*-benzyl-*myo*-inositol-1,3,5-orthobenzoate (6)




Figure S8. ^1H NMR spectrum (CDCl_3) of heated sample of racemic 4-*O*-benzyl-*myo*-inositol - 1,3,5-orthobenzoate (**6**).




Figure S9. Simulated PXRD patterns for crystals of **4**.




Figure S10. PXRD patterns for crystals of (a) black – sample **4D** and (b) blue - Form I.




Figure S11. PXRD patterns for solid forms of **4**. (a) black – solid **4D** and (b) red – Form II.




Figure S12. PXRD patterns of sample **4D**, Form I and Form II crystals

